Substance / Medication

Dimercaprol

Overview

Active Ingredient
dimercaprol
RxNorm CUI
3445

Indications

BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by othe

Labeler: AkornUpdated: 2022-06-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

BAL in Oil (Dimercaprol Injection USP) is contraindicated in most instances of hepatic insufficiency with the exception of postarsenical jaundice. The drug should be discontinued or used only with extreme caution if acute renal insufficiency develops during therapy.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effectiveness of educational interventions for the prevention of lead poisoning in children: a systematic review.
Balza Joanna, Bikomeye Jean C, Flynn Kathryn E · Rev Environ Health · 2025
PMID: 38421442Meta-Analysis
A review of lead exposure source attributional studies.
Kinally Christopher, Fuller Richard, Larsen Bjorn et al. · Sci Total Environ · 2025
PMID: 40532468Meta-Analysis
Lead in traditional and complementary medicine: a systematic review.
McRae Angus, Vilcins Dwan, Le Hong Huynh Thi Cam et al. · Rev Environ Health · 2024
PMID: 36322973Meta-Analysis
Elevated blood lead levels of refugee children in the United States: a systematic review of recent literature (2011-2021).
Balza Joanna S, Bikomeye Jean C, Beyer Kirsten M M et al. · Rev Environ Health · 2023
PMID: 35443103Meta-Analysis
Blood lead levels of children exposed to e-waste: a systematic review and meta-analysis.
Huang Jintao, Zeng Zhijun, Xu Xijin et al. · Environ Sci Pollut Res Int · 2023
PMID: 37097575Meta-Analysis
Effectiveness of interventions for the remediation of lead-contaminated soil to prevent or reduce lead exposure - A systematic review.
Dobrescu Andreea-Iulia, Ebenberger Agnes, Harlfinger Julia et al. · Sci Total Environ · 2022
PMID: 34844314Meta-AnalysisFull text (PMC)
A review of studies on blood lead concentrations of traditional Mexican potters.
Estévez-García Jesús Alejandro, Farías Paulina, Tamayo-Ortiz Marcela · Int J Hyg Environ Health · 2022
PMID: 34954665Meta-Analysis
Role of environmental lead in the occurrence of anemia in Indian children: a systematic review and meta-analysis.
Malik Vivek Singh, Singh Manvi, Pradhan Pranita et al. · Environ Sci Pollut Res Int · 2022
PMID: 35066849Meta-Analysis
Association between blood lead levels and markers of calcium homeostasis: a systematic review and meta-analysis.
Upadhyay Kuldip, Viramgami Ankit, Bagepally Bhavani Shankara et al. · Sci Rep · 2022
PMID: 35115666Meta-AnalysisFull text (PMC)
Systemic review of genetic and epigenetic factors underlying differential toxicity to environmental lead (Pb) exposure.
Cuomo Danila, Foster Margaret J, Threadgill David · Environ Sci Pollut Res Int · 2022
PMID: 35244845Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dimercaprol (substance)
SNOMED CT
387077001
UMLS CUI
C0012383
RxNorm CUI
3445
Labeler
Akorn

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.